These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 28600471)

  • 21. Anti-hypertensive effects of shichimotsukokato in 5/6 nephrectomized Wistar rats mediated by the DDAH-ADMA-NO pathway.
    Bai F; Makino T; Ono T; Mizukami H
    J Nat Med; 2012 Oct; 66(4):583-90. PubMed ID: 22350214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine.
    Kajimoto H; Kai H; Aoki H; Yasuoka S; Anegawa T; Aoki Y; Ueda S; Okuda S; Imaizumi T
    Kidney Int; 2012 Apr; 81(8):762-8. PubMed ID: 22297680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents.
    Kaufman JS
    Am J Kidney Dis; 2013 Feb; 61(2):191-3. PubMed ID: 23318011
    [No Abstract]   [Full Text] [Related]  

  • 24. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis.
    Jacobi J; Sydow K; von Degenfeld G; Zhang Y; Dayoub H; Wang B; Patterson AJ; Kimoto M; Blau HM; Cooke JP
    Circulation; 2005 Mar; 111(11):1431-8. PubMed ID: 15781754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
    Milovanov IuS; Milovanova LIu
    Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease.
    Martinez-Vea A; Marcas L; Bardají A; Romeu M; Gutierrez C; García C; Compte T; Nogues R; Peralta C; Giralt M
    Clin Nephrol; 2012 Mar; 77(3):171-81. PubMed ID: 22377247
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of lowering asymmetric dimethylarginine (ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass.
    Jacobi J; Maas R; Arend M; Cordasic N; Hilgers KF
    Int J Mol Sci; 2014 Mar; 15(4):5522-35. PubMed ID: 24690995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase.
    Ueda S; Kato S; Matsuoka H; Kimoto M; Okuda S; Morimatsu M; Imaizumi T
    Circ Res; 2003 Feb; 92(2):226-33. PubMed ID: 12574151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of anemia correction by erythropoiesis-stimulating agents on cardiovascular function in non-dialysis patients with chronic kidney disease.
    Suzuki M; Hada Y; Akaishi M; Hiroe M; Aonuma K; Tsubakihara Y; Akizawa T
    Int Heart J; 2012; 53(4):238-43. PubMed ID: 22878802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase.
    Scalera F; Kielstein JT; Martens-Lobenhoffer J; Postel SC; Täger M; Bode-Böger SM
    J Am Soc Nephrol; 2005 Apr; 16(4):892-8. PubMed ID: 15728783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anemia management in chronic kidney disease: bursting the hemoglobin bubble.
    Weiner DE; Miskulin DC
    Ann Intern Med; 2010 Jul; 153(1):53-5. PubMed ID: 20439567
    [No Abstract]   [Full Text] [Related]  

  • 32. Severely decreased activity of placental dimethylarginine dimethylaminohydrolase in pre-eclampsia.
    Anderssohn M; Maass LM; Diemert A; Lüneburg N; Atzler D; Hecher K; Böger RH
    Eur J Obstet Gynecol Reprod Biol; 2012 Apr; 161(2):152-6. PubMed ID: 22285683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardio-renal-anemia syndrome: a link between erythropoietin, dimethylarginine and homocysteine.
    Righetti M
    Curr Med Chem; 2012; 19(21):3502-7. PubMed ID: 22680636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymmetric dimethylarginine, an endogenous NOS inhibitor, is actively metabolized in rat erythrocytes.
    Yokoro M; Suzuki M; Murota K; Otsuka C; Yamashita H; Takahashi Y; Tsuji H; Kimoto M
    Biosci Biotechnol Biochem; 2012; 76(7):1334-42. PubMed ID: 22785485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression?
    Malyszko J; Glowinska I; Mysliwiec M
    Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to Recombinant Human Erythropoietin Therapy in a Rat Model of Chronic Kidney Disease Associated Anemia.
    Garrido P; Ribeiro S; Fernandes J; Vala H; Rocha-Pereira P; Bronze-da-Rocha E; Belo L; Costa E; Santos-Silva A; Reis F
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs for treatment of anemia of chronic kidney disease.
    Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
    Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5.
    Rianthavorn P; Boonyapapong P
    Pediatr Nephrol; 2013 Aug; 28(8):1261-6. PubMed ID: 23420502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats.
    Serizawa K; Yogo K; Tashiro Y; Aizawa K; Kawasaki R; Hirata M; Endo K
    Eur J Pharmacol; 2015 Nov; 767():10-6. PubMed ID: 26432688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.